Furthermore, one of the genes we identified as more highly expressed by non-Vδ1Vδ2 cells was TGFBI. TGFBI has been implicated in tumour progression, and elevated levels have been associated with a poor clinical outcome, as it promotes angiogenesis and tumour cell migration, not least in CRC [40], and also reduces T cell activation [41, 42]. The gene discussed is TGFBI; the disease is neoplasm.